Long-term outcomes with ruxolitinib and best available therapy for the treatment of myelofibrosis

Share :
Published: 19 Jun 2013
Views: 5673
Prof Alessandro Vannucchi - University of Florence, Florence, Italy

Prof Alessandro Vannucchi talks to ecancer at the 18th EHA Congress in Stockholm about a phase III clinical trial that examined the outcomes of treating myelofibrosis with ruxolitinib and the best available therapy.